Results 11 to 20 of about 9,484 (203)
Journal of Ophthalmology, 2021 Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. This meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost ...
Ziyan Cai +3 more
doaj +1 more source
Journal of Ophthalmology, 2022 Background: Prostaglandin analogs (e.g., latanoprost) are the first-line therapy for glaucoma. These medications, however, have a short antihypertensive effect due to low penetration of topical drug across the corneal epithelium, which causes the need ...
I. M. Mikheytseva +5 more
doaj +1 more source
Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma [PDF]
Clinics, 2020 OBJECTIVES: Timolol maleate has been reported to be a safer intraocular pressure (IOP) lowering treatment than latanoprost. The United States Food and Drug Administration approved latanoprostene bunod, a nitric oxide-donating prodrug of latanoprost, for ...
Yulong Wang, Yue Liao, Xin Nie
doaj +1 more source
Российский офтальмологический журнал, 2023 The number of ophthalmic antihypertensive drugs available in Russia is steadily increasing, which complicates the choice to be made by ophthalmologist practitioners.
D. P. Novikov +3 more
doaj +1 more source
Extended Latanoprost Release from Commercial Contact Lenses: In Vitro Studies Using Corneal Models [PDF]
, 2014 Mohammadi, S., Jones, L., & Gorbet, M. (2014). Extended Latanoprost Release from Commercial Contact Lenses: In Vitro Studies Using Corneal Models. PLoS ONE, 9(9), e106653.
Gorbet, Maud +2 more
core +5 more sources
Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat
Ophthalmology and Therapy, 2020 Purpose Instillation of latanoprost eye drops into the conjunctival sac to lower intraocular pressure (IOP) is the most frequently used treatment for primary open-angle glaucoma.
Maciej Świątkiewicz +5 more
doaj +1 more source
Frontiers in Medicine, 2022 ObjectiveAs monotherapy is insufficient for some patients, the existing fixed-dose combination (FDC) requires two or more daily administrations with declining adherence.
Nachuan Luo +9 more
doaj +1 more source
Reliable intraocular pressure measurement using automated radio-wave telemetry [PDF]
, 2014 Purpose To present an autonomous intraocular pressure (IOP) measurement technique using a wireless implantable transducer (WIT) and a motion sensor. Methods: The WIT optical aid was implanted within the ciliary sulcus of a normotensive rabbit eye after ...
Cade, Fabiano +5 more
core +3 more sources
Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany
International Journal of Ophthalmology, 2013 AIM: To evaluate 5-year effectiveness and cost between latanoprost or timolol monotherapy in a pilot trial. METHODS: A retrospective, multi-center trial performed at 6 sites in Germany of patients who had a diagnosis of primary open-angle or ...
Jeanette A. Stewart +6 more
doaj +1 more source
Rare diseases leading to childhood Glaucoma. epidemiology, pathophysiogenesis, and management [PDF]
, 2015 Noteworthy heterogeneity exists in the rare diseases associated with childhood glaucoma. Primary congenital glaucoma is mostly sporadic; however, 10% to 40% of cases are familial. CYP1B1 gene mutations seem to account for 87% of familial cases and 27% of
Abdolrahimzadeh, Solmaz +5 more
core +3 more sources